{"success":true,"data":{"pressRelease":{"id":"50800","rtpr_id":"nGNX6HfXGr","ticker":"LIXT","exchange":"NASDAQ","all_tickers":["LIXT"],"title":"LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors","author":"Globe Newswire","published_at":"2026-06-01T12:50:00.118Z","article_body":"Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter\nHas Helped Build a Global Power Infrastructure Portfolio, Strengthening\nLIXTE’s Strategic Expansion into AI Energy Infrastructure\n\nBOCA RATON, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology\nHoldings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today\nannounced its strategic transformation into an AI energy infrastructure\nequipment & services platform focused on meeting the rapidly growing power\ndemands of AI and hyperscale data centers. In connection with this\ntransformation, Stuart D. Porter, Founder, Managing Partner, Chief Executive\nOfficer and Chief Investment Officer of Denham Capital Management LP, will\njoin the Company’s Board of Directors, effective today. The Company also\nannounced it will seek a strategic acquisition partner for its clinical stage\npharmaceutical and med-tech operations that are focused on advancing cancer\ntreatments.\n\nStrategic Transformation into AI Energy Infrastructure Equipment & Services\n\nLIXTE’s transformation comes amid a widening gap between North American\nelectricity demand and available generation capacity, driven largely by the\nrapid expansion of AI and hyperscale data centers. In its January 2026\nLong-Term Reliability Assessment, the North American Electric Reliability\nCorporation (NERC) projected summer peak demand will increase by 224 gigawatts\nover the next decade while warning that several major grid regions face\nelevated risk of supply shortfalls. In April 2026, NERC issued a rare Level 3\nAlert directing grid operators to address reliability risks tied to\nlarge-scale computational loads.\n\n“The power problem is the AI problem,” said Geordan Pursglove, Chief\nExecutive Officer of LIXTE. “Compute capacity is being built faster than the\ngrid can support it. Hyperscale operators, sovereign AI programs and\nnext-generation inference applications all face the same constraint: reliable\npower. We believe LIXTE is positioned to become a focused public-market\nplatform addressing that challenge by helping debottleneck the power\ninfrastructure.”\n\nLIXTE’s strategy will focus on:\n\n• Power equipment and service solutions for hyperscale AI and data-center\ncampuses, including long-duration generation, co-located power assets and\ngrid-edge infrastructure.\n• Equipment for distributed and behind-the-meter power systems supporting\nenterprise AI, sovereign compute and edge inference deployments.\n• Strategic acquisitions and partnerships targeting advanced generation\ntechnologies.\n\nLIXTE expects to maintain its Nasdaq listing under the ticker symbol\n“LIXT” during the transformation process. Additional details regarding the\nCompany’s strategic initiatives, transaction pipeline and management\nadditions are expected to be announced in future public disclosure filings and\nupdates.\n\n“This is a deliberate repositioning of LIXTE toward one of the largest\ninfrastructure opportunities emerging in North American energy,” Pursglove\nadded. “We intend to build a focused, execution-driven company designed for\nthe accelerating AI economy.”\n\nAppointment of Stuart D. Porter to Board of Directors\n\nMr. Porter founded Denham Capital in 2004 and has overseen more than $12\nbillion of invested and committed capital across the energy and\nenergy-transition sectors. Denham Capital’s infrastructure group is\nadvancing a U.S. & European pipeline of roughly 10 GW of AI\ndata-center-oriented power generation asset opportunities to support the data\ncenter buildout, drawing on its deep execution experience in developing,\nbuilding and financing large scale gas, renewable and storage projects\nglobally.\n\n“This is a generational dislocation between compute demand and reliable,\ndispatchable power,” said Stuart D. Porter. “The anticipated AI build-out\nwill require disciplined capital allocation, operational execution and\nlong-duration infrastructure investment. I believe LIXTE has the opportunity\nto become a differentiated public-market vehicle focused on meeting that\ndemand with power equipment and service solutions, and I look forward to\nworking with the Board and management team as the Company executes this\nstrategy.”\n\n“Stu’s addition to our Board underscores the seriousness of LIXTE’s\nplanned transformation,” Pursglove added. “Few investors globally have\ndeployed multi-gigawatt energy portfolios at institutional scale while also\ndeveloping infrastructure specifically tied to the AI power thesis. His front\nline experience with power infrastructure assets will be invaluable as we\nposition LIXTE for long-term growth delivering power equipment and services to\nthe Ai market.”\n\nAbout LIXTE Biotechnology Holdings, Inc.\n\nLIXTE Biotechnology Holdings, Inc\n(https://www.globenewswire.com/Tracker?data=F245JhGfoh1vrKGlLtBI6BO2nV1hdn3gClxOo6WYUZ-vk1bDN5z6pGCQLocyvm2Fcos0HP_6JdbxHBHvhAgXhPuuePbLawE1ilk5dW2ogjc=).\nis a clinical-stage pharmaceutical and med-tech company focused on new targets\nfor cancer drug development and developing and commercializing cancer\ntherapies. LIXTE has demonstrated that LB-100, its lead compound and\nfirst-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer\npatients at doses associated with anti-cancer activity. Based on published\npreclinical data, LB-100 has the potential to significantly enhance\nchemotherapies and immunotherapies and improve outcomes for patients with\ncancer. It is part of a pioneering effort in an entirely new field of cancer\nbiology – activation lethality – that is advancing a new treatment\nparadigm. LIXTE's novel approach is covered by a comprehensive patent\nportfolio, with proof-of-concept clinical trials currently in progress for\nOvarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue\nSarcoma. Additional information can be found at www.lixte.com.\n\nThrough LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the\nCompany also is pioneering the development of electronically controlled proton\ntherapy systems for treating tumors in various types of cancers. Liora’s\nproprietary flagship technology, LiGHT System, is believed to provide\nsignificant advantages over currently available technologies for treating\ntumors with proton therapy. Additional information about Liora Technologies\ncan be found at www.lioratechnologies.com.\n\nForward-Looking Statement Disclaimer\n\nThis announcement contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933, and Section 21E of the\nSecurities Exchange Act of 1934. For example, statements regarding the\nCompany's financial position, business strategy and other plans and objectives\nfor future operations, and assumptions and predictions about future\nactivities, including the continuing development of proprietary compounds, the\nplanning, funding, coordination and potential results of clinical trials, the\npatent and legal costs to protect and maintain the Company's intellectual\nproperty worldwide, are all forward-looking statements. These statements are\ngenerally accompanied by words such as \"intend,\" anticipate,\" \"believe,\"\n\"estimate,\" \"potential(ly),\" \"continue,\" \"forecast,\" \"predict,\" \"plan,\" \"may,\"\n\"will,\" \"could,\" \"would,\" \"should,\" \"expect\" or the negative of such terms or\nother comparable terminology.\n\nThe Company believes that the assumptions and expectations reflected in such\nforward-looking statements are reasonable, based on information available to\nit on the date hereof, but the Company cannot provide assurances that these\nassumptions and expectations will prove to have been correct or that the\nCompany will take any action that the Company may presently be planning.\nHowever, these forward-looking statements are inherently subject to known and\nunknown risks and uncertainties. Actual results or experience may differ\nmaterially from those expected or anticipated in the forward-looking\nstatements. Factors that could cause or contribute to such differences\ninclude, but are not limited to, regulatory policies, available cash\nresources, research results, competition from other similar businesses, and\nmarket and general economic factors.\n\nReaders are urged to read the risk factors set forth in the Company’s\nfilings with the United States Securities and Exchange Commission at\nwww.sec.gov. The Company disclaims any intention or obligation to update or\nrevise any forward-looking statements, whether as a result of new information,\nfuture events or otherwise, except as required by law.\n\nFor more information about LIXTE, contact: \n\ninfo@lixte.com\nGeneral Phone: (631) 830-7092; Investor Phone: (888) 289-5533\nor\nPondelWilkinson Inc. Investor Relations pwinvestor@pondel.com\nRoger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7e828ef4-6c8f-4c94-b376-4e3749530fba)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6HfXGr","title":"LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors","author":"Globe Newswire","ticker":"LIXT","created":"2026-06-01T12:50:00.118Z","tickers":["LIXT"],"exchange":"NASDAQ","article_body":"Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter\nHas Helped Build a Global Power Infrastructure Portfolio, Strengthening\nLIXTE’s Strategic Expansion into AI Energy Infrastructure\n\nBOCA RATON, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology\nHoldings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today\nannounced its strategic transformation into an AI energy infrastructure\nequipment & services platform focused on meeting the rapidly growing power\ndemands of AI and hyperscale data centers. In connection with this\ntransformation, Stuart D. Porter, Founder, Managing Partner, Chief Executive\nOfficer and Chief Investment Officer of Denham Capital Management LP, will\njoin the Company’s Board of Directors, effective today. The Company also\nannounced it will seek a strategic acquisition partner for its clinical stage\npharmaceutical and med-tech operations that are focused on advancing cancer\ntreatments.\n\nStrategic Transformation into AI Energy Infrastructure Equipment & Services\n\nLIXTE’s transformation comes amid a widening gap between North American\nelectricity demand and available generation capacity, driven largely by the\nrapid expansion of AI and hyperscale data centers. In its January 2026\nLong-Term Reliability Assessment, the North American Electric Reliability\nCorporation (NERC) projected summer peak demand will increase by 224 gigawatts\nover the next decade while warning that several major grid regions face\nelevated risk of supply shortfalls. In April 2026, NERC issued a rare Level 3\nAlert directing grid operators to address reliability risks tied to\nlarge-scale computational loads.\n\n“The power problem is the AI problem,” said Geordan Pursglove, Chief\nExecutive Officer of LIXTE. “Compute capacity is being built faster than the\ngrid can support it. Hyperscale operators, sovereign AI programs and\nnext-generation inference applications all face the same constraint: reliable\npower. We believe LIXTE is positioned to become a focused public-market\nplatform addressing that challenge by helping debottleneck the power\ninfrastructure.”\n\nLIXTE’s strategy will focus on:\n\n• Power equipment and service solutions for hyperscale AI and data-center\ncampuses, including long-duration generation, co-located power assets and\ngrid-edge infrastructure.\n• Equipment for distributed and behind-the-meter power systems supporting\nenterprise AI, sovereign compute and edge inference deployments.\n• Strategic acquisitions and partnerships targeting advanced generation\ntechnologies.\n\nLIXTE expects to maintain its Nasdaq listing under the ticker symbol\n“LIXT” during the transformation process. Additional details regarding the\nCompany’s strategic initiatives, transaction pipeline and management\nadditions are expected to be announced in future public disclosure filings and\nupdates.\n\n“This is a deliberate repositioning of LIXTE toward one of the largest\ninfrastructure opportunities emerging in North American energy,” Pursglove\nadded. “We intend to build a focused, execution-driven company designed for\nthe accelerating AI economy.”\n\nAppointment of Stuart D. Porter to Board of Directors\n\nMr. Porter founded Denham Capital in 2004 and has overseen more than $12\nbillion of invested and committed capital across the energy and\nenergy-transition sectors. Denham Capital’s infrastructure group is\nadvancing a U.S. & European pipeline of roughly 10 GW of AI\ndata-center-oriented power generation asset opportunities to support the data\ncenter buildout, drawing on its deep execution experience in developing,\nbuilding and financing large scale gas, renewable and storage projects\nglobally.\n\n“This is a generational dislocation between compute demand and reliable,\ndispatchable power,” said Stuart D. Porter. “The anticipated AI build-out\nwill require disciplined capital allocation, operational execution and\nlong-duration infrastructure investment. I believe LIXTE has the opportunity\nto become a differentiated public-market vehicle focused on meeting that\ndemand with power equipment and service solutions, and I look forward to\nworking with the Board and management team as the Company executes this\nstrategy.”\n\n“Stu’s addition to our Board underscores the seriousness of LIXTE’s\nplanned transformation,” Pursglove added. “Few investors globally have\ndeployed multi-gigawatt energy portfolios at institutional scale while also\ndeveloping infrastructure specifically tied to the AI power thesis. His front\nline experience with power infrastructure assets will be invaluable as we\nposition LIXTE for long-term growth delivering power equipment and services to\nthe Ai market.”\n\nAbout LIXTE Biotechnology Holdings, Inc.\n\nLIXTE Biotechnology Holdings, Inc\n(https://www.globenewswire.com/Tracker?data=F245JhGfoh1vrKGlLtBI6BO2nV1hdn3gClxOo6WYUZ-vk1bDN5z6pGCQLocyvm2Fcos0HP_6JdbxHBHvhAgXhPuuePbLawE1ilk5dW2ogjc=).\nis a clinical-stage pharmaceutical and med-tech company focused on new targets\nfor cancer drug development and developing and commercializing cancer\ntherapies. LIXTE has demonstrated that LB-100, its lead compound and\nfirst-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer\npatients at doses associated with anti-cancer activity. Based on published\npreclinical data, LB-100 has the potential to significantly enhance\nchemotherapies and immunotherapies and improve outcomes for patients with\ncancer. It is part of a pioneering effort in an entirely new field of cancer\nbiology – activation lethality – that is advancing a new treatment\nparadigm. LIXTE's novel approach is covered by a comprehensive patent\nportfolio, with proof-of-concept clinical trials currently in progress for\nOvarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue\nSarcoma. Additional information can be found at www.lixte.com.\n\nThrough LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the\nCompany also is pioneering the development of electronically controlled proton\ntherapy systems for treating tumors in various types of cancers. Liora’s\nproprietary flagship technology, LiGHT System, is believed to provide\nsignificant advantages over currently available technologies for treating\ntumors with proton therapy. Additional information about Liora Technologies\ncan be found at www.lioratechnologies.com.\n\nForward-Looking Statement Disclaimer\n\nThis announcement contains certain forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933, and Section 21E of the\nSecurities Exchange Act of 1934. For example, statements regarding the\nCompany's financial position, business strategy and other plans and objectives\nfor future operations, and assumptions and predictions about future\nactivities, including the continuing development of proprietary compounds, the\nplanning, funding, coordination and potential results of clinical trials, the\npatent and legal costs to protect and maintain the Company's intellectual\nproperty worldwide, are all forward-looking statements. These statements are\ngenerally accompanied by words such as \"intend,\" anticipate,\" \"believe,\"\n\"estimate,\" \"potential(ly),\" \"continue,\" \"forecast,\" \"predict,\" \"plan,\" \"may,\"\n\"will,\" \"could,\" \"would,\" \"should,\" \"expect\" or the negative of such terms or\nother comparable terminology.\n\nThe Company believes that the assumptions and expectations reflected in such\nforward-looking statements are reasonable, based on information available to\nit on the date hereof, but the Company cannot provide assurances that these\nassumptions and expectations will prove to have been correct or that the\nCompany will take any action that the Company may presently be planning.\nHowever, these forward-looking statements are inherently subject to known and\nunknown risks and uncertainties. Actual results or experience may differ\nmaterially from those expected or anticipated in the forward-looking\nstatements. Factors that could cause or contribute to such differences\ninclude, but are not limited to, regulatory policies, available cash\nresources, research results, competition from other similar businesses, and\nmarket and general economic factors.\n\nReaders are urged to read the risk factors set forth in the Company’s\nfilings with the United States Securities and Exchange Commission at\nwww.sec.gov. The Company disclaims any intention or obligation to update or\nrevise any forward-looking statements, whether as a result of new information,\nfuture events or otherwise, except as required by law.\n\nFor more information about LIXTE, contact: \n\ninfo@lixte.com\nGeneral Phone: (631) 830-7092; Investor Phone: (888) 289-5533\nor\nPondelWilkinson Inc. Investor Relations pwinvestor@pondel.com\nRoger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7e828ef4-6c8f-4c94-b376-4e3749530fba)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-01T12:50:00.155459831Z","server_sent_at_ms":1780318200155},"received_at":"2026-06-01T12:50:00.281Z","source_url":null},"analysis":{"id":"40232","press_release_id":"50800","analysis_json":{"industry":{"label":"Electrical Equipment","sector":"Industrials"},"redFlags":["Company is abandoning its core clinical-stage biotech business (LB-100, LiGHT System) with no immediate revenue replacement.","Strategic pivot to a completely different industry (energy infrastructure) carries high execution and integration risk.","No specific acquisition target or transaction details provided for the new energy business; pipeline is speculative.","Existing biotech assets are being sold off, likely at a discount, which may result in significant write-downs or dilution."],"eventType":"restructuring","narrative":"LIXTE Biotechnology Holdings announced a strategic transformation from a clinical-stage cancer drug developer into an AI energy infrastructure equipment and services platform.\n\nThe company will seek a strategic acquisition partner for its existing pharmaceutical and med-tech operations, effectively exiting the biotech business to focus on power solutions for hyperscale data centers.\n\nStuart D. Porter, founder of Denham Capital, joins the board to leverage his $12 billion energy portfolio and 10 GW pipeline of AI data-center power assets.\n\nCEO Geordan Pursglove cited a widening gap between electricity demand and generation capacity as the primary driver, positioning LIXTE to address power constraints for AI compute.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"LIXT pivots from biotech to AI energy infrastructure, joining the wave of SPAC-like transformations targeting the data center power boom."},"keyFigures":{"customDimensions":{"denham_capital_managed":"$12 billion","denham_pipeline_capacity":"10 GW","projected_demand_increase":"224 gigawatts"}},"quotedText":"The power problem is the AI problem","namedEntities":{"people":[{"name":"Stuart D. Porter","role":"Founder, Managing Partner, CEO and CIO of Denham Capital; New Board Member"},{"name":"Geordan Pursglove","role":"CEO of LIXTE"},{"name":"Roger Pondel","role":"Investor Relations Contact"},{"name":"Laurie Berman","role":"Investor Relations Contact"}],"products":["LB-100","LiGHT System"],"companies":[{"name":"LIXTE Biotechnology Holdings, Inc.","ticker":"LIXT","relationship":"filer"},{"name":"Denham Capital Management LP","relationship":"partner/investor"},{"name":"North American Electric Reliability Corporation","relationship":"regulatory body cited"},{"name":"Liora Technologies Europe Ltd.","relationship":"subsidiary"},{"name":"PondelWilkinson Inc.","relationship":"investor relations firm"}],"dollarAmounts":[{"amount":"$12 billion","context":"invested and committed capital overseen by Stuart D. Porter at Denham Capital"}]},"materialImpact":{"score":4,"reasoning":"The company is executing a fundamental strategic pivot from clinical-stage biotech to AI energy infrastructure, effectively abandoning its core pharmaceutical business. This is a high-risk, high-reward transformation that changes the company's entire valuation thesis and risk profile. The addition of a seasoned energy investor to the board adds credibility but does not mitigate the execution risk of such a drastic shift."},"tickerRelevance":{"others":[],"primary":"LIXT"},"globalImportance":35,"audienceRelevance":45,"eventTypeSecondary":["board_change"],"importanceComponents":{"riskFactor":"high (execution risk of pivot)","tickerTier":"small-cap","eventGravity":"high (strategic pivot)","sectorWeight":"high (AI/Energy theme)","retailFavoriteBoost":"moderate (AI narrative appeal)"}},"event_type":"restructuring","event_type_secondary":["board_change"],"sentiment":"mixed","material_impact_score":4,"narrative":"LIXTE Biotechnology Holdings announced a strategic transformation from a clinical-stage cancer drug developer into an AI energy infrastructure equipment and services platform.\n\nThe company will seek a strategic acquisition partner for its existing pharmaceutical and med-tech operations, effectively exiting the biotech business to focus on power solutions for hyperscale data centers.\n\nStuart D. Porter, founder of Denham Capital, joins the board to leverage his $12 billion energy portfolio and 10 GW pipeline of AI data-center power assets.\n\nCEO Geordan Pursglove cited a widening gap between electricity demand and generation capacity as the primary driver, positioning LIXTE to address power constraints for AI compute.","key_figures":{"customDimensions":{"denham_capital_managed":"$12 billion","denham_pipeline_capacity":"10 GW","projected_demand_increase":"224 gigawatts"}},"named_entities":{"people":[{"name":"Stuart D. Porter","role":"Founder, Managing Partner, CEO and CIO of Denham Capital; New Board Member"},{"name":"Geordan Pursglove","role":"CEO of LIXTE"},{"name":"Roger Pondel","role":"Investor Relations Contact"},{"name":"Laurie Berman","role":"Investor Relations Contact"}],"products":["LB-100","LiGHT System"],"companies":[{"name":"LIXTE Biotechnology Holdings, Inc.","ticker":"LIXT","relationship":"filer"},{"name":"Denham Capital Management LP","relationship":"partner/investor"},{"name":"North American Electric Reliability Corporation","relationship":"regulatory body cited"},{"name":"Liora Technologies Europe Ltd.","relationship":"subsidiary"},{"name":"PondelWilkinson Inc.","relationship":"investor relations firm"}],"dollarAmounts":[{"amount":"$12 billion","context":"invested and committed capital overseen by Stuart D. Porter at Denham Capital"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-01T12:51:31.552Z","global_importance":35,"audience_relevance":45,"importance_components":{"riskFactor":"high (execution risk of pivot)","tickerTier":"small-cap","eventGravity":"high (strategic pivot)","sectorWeight":"high (AI/Energy theme)","retailFavoriteBoost":"moderate (AI narrative appeal)"}},"durationMs":91265,"modelName":"george-droid-qwen-72b"}}